扶正消癥方对Ⅰb、Ⅱ期HBV-HCC患者微创术后T细胞亚群的影响

Effect of Fuzheng Xiaozheng Prescription on T Cell Subsets in Patients with HBV-HCC of StageⅠb andⅡafter Minimally Invasive Surgery

目的:观察扶正消癥方对Ⅰb、Ⅱ期微创术后的乙型肝炎病毒相关性肝细胞癌(hepatitis B virus associated hepatocellular carcinoma,HBV-HCC)患者复发率、T细胞亚群的影响。方法:选取65例微创术后2个月内的HBV-HCC患者,随机分为试验组33例、对照组32例。对照组给予基础抗病毒治疗联合胸腺肽α1注射液,试验组在对照组治疗基础上给予扶正消癥方,两组均治疗3个月。比较治疗前后患者复发率、T细胞亚群、卡氏评分、肝功能。结果:治疗后,试验组复发率为9.09%,对照组复发率为21.88%,试验组显著低于对照组(P<0.05)。治疗后,试验组丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天冬氨酸转氨酶(aspartate transaminase,AST)、甲胎蛋白(alpha fetoprotein,AFP)显著低于治疗前(P<0.05),试验组ALT、AST、AFP显著低于对照组(P<0.05)。治疗后,试验组卡氏评分显著高于治疗前(P<0.05),试验组卡氏评分显著高于对照组(P<0.05)。治疗后,试验组CD3^(+)、CD3^(+)CD4^(+)、CD4^(+)/CD8^(+)显著高于治疗前(P<0.05),试验组CD3^(+)、CD3^(+)CD4^(+)、CD4^(+)/CD8^(+)显著高于对照组(P<0.05);治疗后,试验组CD3^(+)CD8^(+)显著低于治疗前(P<0.05),试验组CD3^(+)CD8^(+)显著低于对照组(P<0.05)。结论:扶正消癥方能够降低HBV-HCC患者近期复发率,可提高生活质量,改善肝功能、细胞免疫功能。

Objective:To observe the effect of Fuzheng Xiaozheng Prescription on the recurrence rate and T cell subsets of patients with hepatitis B virus associated hepatocellular carcinom(HBV-HCC)of stageⅠb andⅡminimally invasive surgery.Methods:65 patients with HBV-HCC within 2 months after minimally invasive surgery were randomly divided into experimental group(33 cases)and control group(32 cases).The control group was given basic antiviral therapy combined with thymosinα1 injection,and the experimental group was given Fuzheng Xiaozheng Prescription on the basis of the control group.Both groups were treated for 3 months.The recurrence rate,T cell subsets,Karnofsky score and liver function were compared before and after treatment.Results:After treatment,the recurrence rate of the experimental group was 9.09%,and that of the control group was 21.875%,which was significantly lower than that of the control group(P<0.05).After treatment,the levels of alanine aminotransferase(ALT),aspartate transaminase(AST)and alpha fetoprotein(AFP)in the experimental group were significantly lower than those before treatment(P<0.05),and the levels of ALT,AST and AFP in the experimental group were significantly lower than those in the control group(P<0.05).After treatment,the Karnofsky score of the experimental group was significantly higher than that before treatment(P<0.05),and the karnoky score of the experimental group was significantly higher than that of the control group(P<0.05).After treatment,CD3^(+),CD3^(+)CD4^(+),CD4^(+)/CD8^(+)in the experimental group were significantly higher than those before treatment(P<0.05),and CD3^(+),CD3^(+)CD4^(+),CD4^(+)/CD8^(+)in the experimental group were significantly higher than those in the control group(P<0.05);after treatment,CD3^(+)CD8^(+)in the experimental group was significantly lower than that before treatment(P<0.05),and CD3^(+)CD8^(+)in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion:Fuzheng Xiaozheng Prescription can reduce the short-term recurrence rate of HBV-HCC patients,improve the quality of life,liver function and cellular immune function.